Komori
General Meetings of Shareholders4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

ISS Recommendation Report on the Proposals to Be Submitted to Our Annual General Meeting of Shareholders (For the Company Proposals / Against the Shareholder Proposals)

The Company announced that ISS recommended voting in favor of the Company proposals from Proposal No. 1 through Proposal No. 11 and against the shareholder proposal, Proposal No. 12.

Worth reading
87Important
Scored from 3 of 4 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (5th)
2026
Jun 24
Date and time(start time: Not disclosed)18 days from this disclosure to the meeting
Matters for resolution1 item (0 from the company, 1 from shareholders)
  1. Proposals No. 1 through No. 11 (individual titles: Not disclosed), and Proposal No. 12, "Election of 2 directors who are not Audit and Supervisory Committee members"

    Shareholder Proposal
Shareholder Proposal

Proposal No. 12, "Election of 2 directors who are not Audit and Supervisory Committee members," submitted by Dalton and others. The Board of Directors is opposed.

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (5th)
Date and time24 June 2026 (start time: Not disclosed)
Matters for resolutionProposals No. 1 through No. 11 (individual titles: Not disclosed), and Proposal No. 12, "Election of 2 directors who are not Audit and Supervisory Committee members"
Shareholder ProposalProposal No. 12, "Election of 2 directors who are not Audit and Supervisory Committee members," submitted by Dalton and others. The Board of Directors is opposed.
Items this document does not state (2)
Director nomineePercentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

ISS cited increased confidence in the Company's management execution, including the announcement of the Medium-Term Management Plan 2028, the transition to a company with an Audit and Supervisory Committee, and a Board of Directors in which independent outside directors constitute a majority, as reasons for supporting the Company proposals. With respect to Proposals No. 11 and No. 12, ISS cited the shareholder proponents' intention to acquire additional shares and their failure to provide sufficient specific measures for, or a basis for, enhancing and transforming corporate value after taking office as directors.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
ISS Recommendation Report on the Proposals to Be Submitted to Our Annual General Meeting of Shareholders (For the Company Proposals / Against the Shareholder Proposals) | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori